Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18008 ↗At a glance
Leserbrief in Alimentary Pharmacology & Therapeutics, 2024. Written by Raphael Mohr and 2 co-authors. Institution: Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Disease Progression. 9 references.
Abstract (original language)
LINKED CONTENT This article is linked to Jost‐Brinkmann et al papers. To view these articles, visit https://doi.org/10.1111/apt.17441 and https://doi.org/10.1111/apt.17985
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
ORCID profiles: Raphael Mohr, Frank Tacke
Cite
APA
Mohr, R., Tacke, F., & Roderburg, C. (2024). Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18008
Vancouver
Mohr R, Tacke F, Roderburg C. Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18008
BibTeX
@article{Mohr2024,
author = {Mohr, Raphael and Tacke, Frank and Roderburg, Christoph},
title = {Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma. Authors' reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18008}
}
EUVIMED